Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q3

4564.TEDINET S100Q6XE
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥700m2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥335m2021-04-01 → 2021-12-31Cons.Net sales
Operating income−¥905m2022-04-01 → 2022-12-31Cons.Operating income
Operating income−¥1.7bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income−¥929m2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.7bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax−¥912m2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax−¥2.1bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)−¥913m2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income−¥913m2022-04-01 → 2022-12-31Cons.Profit loss
Net income−¥2.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥1.4bnat 2022-12-31Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥2.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥392mat 2022-12-31Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.1bnat 2022-12-31Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥2.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥978mat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-4.742022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.552022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.522021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-4.732021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio68.1%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio80.5%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥172,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥290m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥691m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥79m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-12-31¥9m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥172,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-12-31−¥536m
—segment totalrevenue2022-04-01 → 2022-12-31¥700m
—segment totalrevenue external2022-04-01 → 2022-12-31¥700m
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥172,000
—segment totalsegment profit2022-04-01 → 2022-12-31−¥615m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥282m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥337m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥329m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥8m
jpcrp040300-q3r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-12-31−¥127m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-12-31¥7m
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥132,000
jpcrp040300-q3r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-12-31−¥1.3bn
—segment totalrevenue2021-04-01 → 2021-12-31¥344m
—segment totalrevenue external2021-04-01 → 2021-12-31¥335m
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥8m
—segment totalsegment profit2021-04-01 → 2021-12-31−¥1.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 322
ItemContextValueUnit
Contract liabilitiesPrior1YearInstant22268000JPY
Contract liabilitiesCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant136533000JPY
Income taxes payableCurrentQuarterInstant35395000JPY
Asset retirement obligations clPrior1YearInstant3678000JPY
Asset retirement obligations clCurrentQuarterInstant72191000JPY
Other clPrior1YearInstant20330000JPY
Other clCurrentQuarterInstant26624000JPY
Current liabilitiesPrior1YearInstant604923000JPY
Current liabilitiesCurrentQuarterInstant347969000JPY
Deferred tax liabilitiesPrior1YearInstant338000JPY
Deferred tax liabilitiesCurrentQuarterInstant－JPY
Asset retirement obligations nclPrior1YearInstant99703000JPY
Asset retirement obligations nclCurrentQuarterInstant44021000JPY
Noncurrent liabilitiesPrior1YearInstant100041000JPY
Noncurrent liabilitiesCurrentQuarterInstant44021000JPY
LiabilitiesPrior1YearInstant704965000JPY
LiabilitiesCurrentQuarterInstant391990000JPY
Capital stockPrior1YearInstant789114000JPY
Capital stockCurrentQuarterInstant789114000JPY
Capital surplusPrior1YearInstant24793617000JPY
Capital surplusCurrentQuarterInstant24793617000JPY
Retained earningsPrior1YearInstant-23686179000JPY
Retained earningsCurrentQuarterInstant-24599376000JPY
Shareholders equityPrior1YearInstant1896553000JPY
Shareholders equityCurrentQuarterInstant983355000JPY
Subscription rights to sharesPrior1YearInstant83680000JPY
Subscription rights to sharesCurrentQuarterInstant68633000JPY
Net assetsPrior1YearInstant1980233000JPY
Net assetsCurrentQuarterInstant1051988000JPY
Liabilities and net assetsPrior1YearInstant2685199000JPY
Liabilities and net assetsCurrentQuarterInstant1443979000JPY
Business revenuePrior1YTDDuration335214000JPY
Business revenueCurrentYTDDuration699689000JPY
Cost of salesPrior1YTDDuration336039000JPY
Cost of salesCurrentYTDDuration715472000JPY
Research and development expenses sgaPrior1YTDDuration1380684000JPY
Research and development expenses sgaCurrentYTDDuration561822000JPY
Selling general and administrative expensesPrior1YTDDuration328805000JPY
Selling general and administrative expensesCurrentYTDDuration327342000JPY
Business expensesPrior1YTDDuration2045529000JPY
Business expensesCurrentYTDDuration1604637000JPY
Operating incomePrior1YTDDuration-1710315000JPY
Operating incomeCurrentYTDDuration-904947000JPY
Interest income noiPrior1YTDDuration146000JPY
Interest income noiCurrentYTDDuration－JPY
Subsidy income noi bountyPrior1YTDDuration389000JPY
Subsidy income noi bountyCurrentYTDDuration－JPY
Interest on refund noiPrior1YTDDuration284000JPY
Interest on refund noiCurrentYTDDuration218000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass